Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Mar 19:9:652842.
doi: 10.3389/fpubh.2021.652842. eCollection 2021.

Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis

Danying Yan  1 , Xiaobao Zhang  1 , Can Chen  1 , Daixi Jiang  1 , Xiaoxiao Liu  1 , Yuqing Zhou  1 , Chenyang Huang  1 , Yiyi Zhou  1 , Zhou Guan  1 , Cheng Ding  1 , Lu Chen  1 , Lei Lan  1 , Xiaofang Fu  1 , Jie Wu  1 , Lanjuan Li  1 , Shigui Yang  1
Affiliations
Meta-Analysis

Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis

Danying Yan et al. Front Public Health. .

Abstract

Background: The viral shedding time (VST) of SARS-CoV-2 mainly determines its transmission and duration of infectiousness. However, it was heterogeneous in the existing studies. Here, we performed a meta-analysis to comprehensively summarize the VST of SARS-CoV-2. Methods: We searched PubMed, Web of Science, MedRxiv, BioRxiv, CNKI, CSTJ, and Wanfang up to October 25, 2020, for studies that reported VSTs of SARS-CoV-2. Pooled estimates and 95% CIs for the VSTs were calculated using log-transformed data. The VSTs in SARS-CoV-2 infections based on different demographic and clinical characteristics, treatments and specimens were stratified by subgroup analysis. Results: A total of 35 studies involving 3,385 participants met the inclusion criteria. The pooled mean VST was 16.8 days (95% CI: 14.8-19.4, I2 = 99.56%) in SARS-CoV-2 infections. The VST was significantly longer in symptomatic infections (19.7 days, 95% CI: 17.2-22.7, I2 = 99.34%) than in asymptomatic infections (10.9 days, 95% CI: 8.3-14.3, I2 = 98.89%) (P < 0.05). The VST was 23.2 days (95% CI: 19.0-28.4, I2 = 99.24%) in adults, which was significantly longer than that in children (9.9 days, 95% CI: 8.1-12.2, I2 = 85.74%) (P < 0.05). The VST was significantly longer in persons with chronic diseases (24.2 days, 95% CI: 19.2-30.2, I2 = 84.07%) than in those without chronic diseases (11.5 days, 95% CI: 5.3-25.0, I2 = 82.11%) (P < 0.05). Persons receiving corticosteroid treatment (28.3 days, 95% CI: 25.6-31.2, I2 = 0.00%) had a longer VST than those without corticosteroid treatment (16.2 days, 95% CI: 11.5-22.5, I2 = 92.27%) (P = 0.06). The VST was significantly longer in stool specimens (30.3 days, 95% CI: 23.1-39.2, I2 = 92.09%) than in respiratory tract specimens (17.5 days, 95% CI: 14.9-20.6, I2 = 99.67%) (P < 0.05). Conclusions: A longer VST was found in symptomatic infections, infected adults, persons with chronic diseases, and stool specimens.

Keywords: COVID-19; SARS- CoV-2; meta-analysis; systematic review; viral shedding time.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process for this meta-analysis.
Figure 2
Figure 2
Forest plot of meta-analysis of log-transformed VST in SARS-CoV-2 infections.
Figure 3
Figure 3
The VST in SARS-CoV-2 infections based on different demographic features, clinical features and treatments. * Unclassified groups were not included in the P-values calculation for the subgroup comparisons. #P-value for comparison between group with antiviral mono-therapy and group with antiviral muti-therapy.
Figure 4
Figure 4
The VST in SARS-CoV-2 infections based on different specimens. *P-value for comparison between respiratory tract specimens and stool specimens.
See this image and copyright information in PMC

Comment in

References

    1. Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical characteristics, diagnosis, and treatment of major coronavirus outbreaks. Front Med. (2020) 7:766. 10.3389/fmed.2020.581521 - DOI - PMC - PubMed
    1. Perisetti A, Gajendran M, Boregowda U, Bansal P, Goyal H. COVID-19 and gastrointestinal endoscopies: current insights and emergent strategies. Dig Endosc. (2020) 32:715–22. 10.1111/den.13693 - DOI - PMC - PubMed
    1. World Coronavirus Death . Coronavirus Death Toll and Trends –Worldometer. (2020). Available online at: https://www.worldometers.info/coronavirus (accessed February 4, 2021).
    1. Perisetti A, Gajendran M, Mann R, Elhanafi S, Goyal H. COVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations. Dis Mon. (2020) 66:101064. 10.1016/j.disamonth.2020.101064 - DOI - PMC - PubMed
    1. Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med. (2020) 7:526. 10.3389/fmed.2020.00526 - DOI - PMC - PubMed

Publication types

Substances